- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02044003
Safety & Feasibility Study of Tack-It Device for Vessel Dissection Repair
Safety & Feasibility Study of the Innovasc Tack Intravascular Staple System (Tack) for Securing Vascular Flaps Resulting From Balloon Angioplasty in the Infrainguinal Artery(Ies)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to evaluate the safety of delivery and placement of the Innovasc Tack Intravascular Staple System on vascular flaps in the SFA, created by percutaneous transluminal balloon angioplasty
Safety will be evaluated as the 30-day (or hospital discharge date, whichever is longer) rate of major adverse events defined as the composite endpoint of death, device embolization, the occurrence of surgery related to the device, device related occlusion of the artery, or major unplanned amputation of the ipsilateral lower extremity.
The secondary objective is to evaluate the feasibility of using the Innovasc Tack Intravascular Staple System to permanently secure vascular flaps.
Secondary Evaluation of Feasibility (technical success) of the Innovasc Tack Intravascular Staple System (procedure and device) will be evaluated acutely by the following:
- Feasibility is defined as the ability to accurately place the Plaque Tacks and resolve post-PTA dissection flaps prior to the conclusion of the procedure, as demonstrated by angiography
- Acute technical success: Acute luminal patency during the revascularization procedure using standard angiography which demonstrates that the lumen of the artery at the location of tack implant remains patent at the conclusion of the procedure.
The additional objectives of the study are to assess additional parameters as follows:
- Long term success will be assessed at one (1) month and three (3) months by evaluation of post-implant stability of the Plaque Tack relative to vascular or external landmarks at 30 days and 3 months via standard x-ray.
- Patency at 30 days and 3 months via duplex scanning or angiography, whichever deemed most appropriate for follow up of each individual patient by the principal investigator.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Asunción, Paraguay
- Italian Hospital (Final treatment hospital and all follow-up)
-
Asunción, Paraguay
- Santa Clara Medical Center (initial treatment hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18 and < 85 years
- Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
- Patient has documented chronic limb ischemia with Rutherford Category 2, 3, 4, or 5. Clinical conditions of claudication or rest pain or ischemic ulceration or minor gangrene as diagnosed by the investigator
- Reference vessel diameter between 2 and 7mm
- Target lesion is not severely calcified
- At least one patent tibial runoff vessel is present.
- Patient has patent iliac or femoral arteries that allow endovascular access to the site with the Introducer Sheath or Delivery Catheter or these can be treated at the time of the procedure and achieve a <30% residual stenosis at each inflow lesion.
- Ability to pass the guidewire across the atherosclerotic lesion.
- No evidence of aneurysm or acute thrombus in target vessel.
Exclusion Criteria:
- Severe or infected gangrene of the lower extremity
- Planned major amputation
- Previously implanted stent at the treatment site
- Patient is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization.
- Patient has connective tissue disease (e.g., Marfan's syndrome).
- Inability to tolerate antiplatelet agents
- Patient is hypercoagulable
- Patient has allergy to vascular contrast for which they cannot be premedicated.
- Patient is in acute renal failure or chronic renal insufficiency or failure as measured by a serum creatinine of >2.2 mg/dL.
- Patient has active systemic infection
- Patient has a less than one year life expectancy.
- Patient is pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Post Angioplasty Dissection Repair
Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
|
Tack-It Dissection repair
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Safety
Time Frame: 30 days
|
Safety will be evaluated as the 30-day (or hospital discharge date, whichever is longer) rate of major adverse events defined as the composite endpoint of death, device embolization, the occurrence of surgery related to the device, device related occlusion of the artery, or major unplanned amputation of the ipsilateral lower extremity.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Feasibility
Time Frame: Conclusion of implant procedure
|
Feasibility (technical success) of the Innovasc Tack Intravascular Staple System (procedure and device) will be evaluated acutely by the following:
|
Conclusion of implant procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of post-implant stability
Time Frame: 30 and 90 days
|
Evaluation of post-implant stability of the Tack relative to vascular or external landmarks at 30 days and 3 months via standard x-ray.
|
30 and 90 days
|
|
Patency
Time Frame: 30 and 90 days
|
Patency at 30 days and 3 months via duplex scanning or angiography, whichever deemed most appropriate for follow up of each individual patient by the principal investigator.
|
30 and 90 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adrian Ebner, MD, Santa Clara Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCCompletedCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Azienda Ospedaliero-Universitaria di ParmaActive, not recruiting
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
XeltisRecruitingPeripheral Artery Occlusive DiseaseCosta Rica
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
BayerCompletedCoronary Artery Disease (CAD) | Prevention of Atherothrombotic Events | Symptomatic Peripheral Artery Disease (Symptomatic PAD)India
Clinical Trials on Innovasc Tack Intravascular Staple System (Tack)
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Artery Disease | Critical Limb IschemiaAustria
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Arterial DiseaseUnited States, Germany, New Zealand, Hungary, Austria, Czechia
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Artery DiseaseUnited States, Austria, Netherlands
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Arterial DiseaseGermany, Austria, Belgium, Switzerland
-
China Medical University HospitalRecruitingDelirium | Agitation | Intensive Care Unit DeliriumTaiwan
-
Spectranetics CorporationTerminatedPeripheral Arterial Disease | Peripheral Vascular Diseases | PAD | PAD - Peripheral Arterial Disease | Dissection | Arterial DissectionUnited States
-
HaEmek Medical Center, IsraelNot yet recruiting